Version history

{
  "session_id": "sess_0ed3c364-07fd-4620-8e90-8bd33c14e370_task_66f1207e_recon",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "scidex.core.llm.complete",
  "action": "assess",
  "content": "Domain expert assessment for analysis 0ed3c364-07fd-4620-8e90-8bd33c14e370: Causal Sequence of TDP-43 Nuclear Clearance to Cytoplasmic Aggregation in ALS Motor Neurons\n\nThe practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational biomarker or intervention point.\n\nFor model systems, prioritize human iPSC-derived disease-relevant cells, co-culture or organoid systems only when the question explicitly requires cross-cell interaction, and mouse models only for organism-level timing or NMJ/vascular phenotypes. Biomarkers should be proximal to mechanism: transcriptional module activity, protein localization, lipid or RNA-modification state, spatial vascular coupling, or motor-unit integrity depending on the gap.\n\nThe development risk is moderate. The question is specific enough to generate falsifiable work, and it is anchored to Molecular Mechanisms of Phase Separation and Amyloidosis of ALS/FTD-linked FUS and TDP-43. The risk is that therapeutic tractability may lag mechanistic clarity: even if RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation is causal, the safest intervention point may be an upstream regulator, a cell-state transition, or a biomarker-guided patient subset rather than the named entity itself.",
  "tokens_used": "421",
  "persona_id": "persona-domain_expert"
}